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Abstract 
Plasma membrane vesicles from HeLa S cells grown in culture bound with high affinity the antitumor sulfonylurea N-(4-methylphen- 
ylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984). Based on binding site protection experiments with the radiolabeled thiol reagent 
N-[t4C]ethylmaleimide, a ca. 34 kDa binding protein was identified. By analogy with a 36 kDa NADH oxidase from plant plasma 
membranes where activity was blocked by a growth-inhibitory herbicidal suifonylurea, the sulfonylurea-binding protein of the HeLa 
plasma membranes has now been identified as a comparable sulfonylurea-inhibited NADH oxidase activity. The drug inhibited half 
maximally at about 50 nM which corresponded closely to the K d for binding of [3H]LYI81984 of 25 nM. A closely related but 
growth-inactive sulfonylurea N-(4-methylphenylsulfonyi)-N'-(phenyl)urea (LYI 81985) inhibited the activity only weakly. The inhibition 
by LY181984 was analyzed kinetically and shown to be noncompetitive or uncompetitive depending on the concentration f NADH. 
With sealed right-side out plasma membrane vesicles, the NADH oxidase activity was about 90% inhibited by 1 /zM LY181984. With 
frozen and thawed plasma membrane vesicles or with vesicles first solubilized with 1% Triton X-100, activity also was inhibited by 
LY181984 and not by LY181985 but the maximum inhibition at 10 p~M LY181984 was about 50%. With plasma membranes from rat 
liver, neither LY181984 nor LY181985 affected the NADH oxidase even in the presence of detergent. Thus, selective inhibition or 
stimulation of the oxidation of NADH of tumor plasma membranes by the antitumor sulfonylurea LY181984 may be related to its 
antitumor activity. 
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1. Introduction 
Homogenates, total particulate and plasma membranes 
of cultured HeLa S cells bound the tritiated antitumor 
sulfonylurea [ 3 H]LY 181984 (N-(4-methylphenyl)-N'-(4- 
chlorophenyl)urea) with high affinity (K  d of 20 to 50 nM) 
[ 1 ]. Highest affinity binding was to purified plasma mem- 
branes (K  d of 25 nM). In a subsequent report [2], a 
binding protein, apparently with one or more thiols in the 
active site, was identified and labeled with radioactive 
thiol reagents in sulfonylurea protection experiments. 
Binding proteins of M r ca. 34 kDa were labeled [2]. 
Abbreviations: LY181984, N-(4-methylphenylsulfonyl)-N'-(4-chloro- 
phenyl)urea; LYl81985, N-(4-methylphenylsulfonyl)-N'-(phenyl)urea; 
Sulofenur, LY186641, N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea. 
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In this report, we provide evidence that the 34 kDa 
sulfonylurea-binding protein has NADH oxidase activity. 
The experimental approach was based on earlier findings 
in plants of an NADH oxidase activity that responded to 
auxin regulators of plant growth [3]. This activity was not 
only stimulated by the auxin regulators but was inhibited 
as well by herbicidal sulfonylureas [4] that at subherbicidal 
concentrations may act as plant growth retardants [5]. As a 
result, the comparable cyanide-resistant oxidation of 
NADH by plasma membranes of HeLa cells was tested for 
inhibition by the antitumor sulfonylurea LY181984. 
LY181984, but not a structurally-related but antitumor-in- 
active sulfonylurea, N-(4-methylphenylsulfonyl)-N'-  
(phenyl)urea (LY 181985), inhibited the activity. By kinetic 
analysis, the inhibition was shown to be uncompetitive or 
noncompetitive depending on NADH concentration. Addi- 
tionally, the comparable cyanide-resistant NADH oxida- 
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tion by liver plasma membranes was not affected by either 
LY181984 or LY181985 in keeping with the antitumor 
specificity of the sulfonylureas. 
Taken together, the findings suggest hat the 34 kDa 
sulfonylurea-binding protein of HeLa plasma membranes 
may be the transformed cell equivalent of the auxin-re- 
sponsive NADH oxidase of plant membranes. The drug 
responsiveness of the HeLa activity provides an important 
difference between this activity and that of a growth 
factor- and hormone-stimulated NADH oxidase of liver 
plasma membranes also resistant o cyanide [6,7]. While 
the growth factor- and hormone-responsiveness of the 
plasma membrane NADH oxidase appeared to be lost 
upon transformation [8,9], the response to sulfonylurea 
provides additional evidence of the existence in mam- 
malian plasma membranes of an NADH oxidase activity 
altered in transformation. 
The sulfonylureas represent a novel series of synthetic 
organic compounds identified as having activity against 
human solid tumors in vivo [10-12]. Known collectively 
as antitumor diarylsulfonylureas (sulfonylureas), the com- 
pounds have a high degree of efficacy and a relatively low 
toxicity [10,12]. Additionally, their mechanism of action, 
while unknown, is apparently unrelated to previously de- 
scribed classes of oncolytic agents [13]. One member of 
the series, Sulofenur, progressed in evaluation to Phase I 
[12,13] and Phase II [14] clinical trials. The sulfonylureas 
were identified as the result of a program of screening 
against in vivo murine solid tumors implanted subcuta- 
neously [11 ]. 
Despite considerable clinical and laboratory data, the 
site of antitumor sulfonylurea ction has remained elusive 
[10,15]. The drugs are membrane active and weak uncou- 
plers of mitochondrial oxidative phosphorylation [ 15-18]. 
There is no evidence for cell cycle specificity of the drugs 
and no inhibition of DNA, RNA or protein synthesis 
[13,15]. The sulfonylureas exhibit few, if any, mechanistic 
parallels to other known antitumor agents [19]. Thus, their 
mode of action is expected to be unique. 
2. Materials and methods 
2.1. Growth of cells 
HeLa S cells were grown on minimal essential medium 
(S-MEM) (Jolik modified) with glutamine (244 mg/1) and 
phosphate (1.3 g / !  Na2HPO 4) and without CaCi 2 plus 5% 
donor horse serum. Gentimycin sulfate (50 mg/l)  and 
sodium bicarbonate (2 g/ l )  were added. Cells were col- 
lected by centrifugation for 6 to 15 min at 1000 to 3000 
rpm (e.g., 6 min at 3000 rpm or 15 min at 1000 rpm). 
Attached HeLa cells (ATCC CCL2), were grown in 150 
cm flasks in minimal essential medium (Gibco), pH 7.4, at 
37°C with 10% bovine calf serum (heat-inactivated), plus 
50 mg/ l  gentimycin sulfate (Sigma). Cells were trypsinized 
with Sigma IX trypsin for 1 to 2 min and harvested by 
scraping and taken up in TD-Tris buffer (140 mM NaCI, 5 
mM KCI, 0.7 mM NazHPO 4 and 25 mM Tris, pH 7.4) to a 
final cell concentration of 0.1 g wet weight per ml. Cell 
survival was determined by Eosin Y exclusion. 
2.2. Purification of plasma membranes from HeLa cells 
HeLa cells grown as suspension cultures were collected 
by centrifugation for 6 to 15 min at 1000 to 3000 rpm 
(e.g., 6 min at 3000 rpm or 15 min at 1000 rpm). The cell 
pellets were resuspended in 0.2 mM EDTA in 1 mM 
NaHCO 3 in an approximate ratio of 1 mi per 108 ceils and 
incubated on ice for 10 to 30 min to swell the cells. 
Homogenization was with a Polytron homogenizer for 30 
to 40 s at 10500 rpm using a PT-PA 3012/23 or ST-probe 
in 7 to 8 ml aliquots. To estimate breakage, the cells were 
monitored by light microscopy before and after homoge- 
nization. At least 90% cell breakage without breakage of 
nuclei was achieved routinely. 
The homogenates were centrifuged for 10 min at 1000 
rpm (175 X g) to remove unbroken cells and nuclei and 
the supernatant was centrifuged a second time for 1 h at 
23 500 X g to prepare aplasma membrane-enriched micro- 
some fraction. The supernatant was discarded and the 
pellets were resuspended in 0.2 M potassium phosphate 
buffer in a ratio of approx. 1 ml per pellet from 5.108 
cells. The resuspended membranes were then loaded onto 
the two-phase system constituted on a weight basis as 
follows. The two-phase system contained 6.6% (w/w) 
Dextran T-500 (Pharmacia), 6.6% (w/w) poly(ethylene 
glycol) 3350 (Fisher), and 5 mM potassium phosphate 
buffer, pH 7.2 [20]. The homogenate (1 g) was added to 
the two-phase system and the weight of the system was 
brought o 8 g with distilled water. The tubes were in- 
verted vigorously for 40 times in the cold (4°C). The 
phases were separated by centrifugation at750 rpm (150 X 
g) in a Sorvall HB 4 rotor for 5 min. The upper phases 
were carefully withdrawn with a pasteur pipette, divided in 
half and transferred into 40 ml plastic centrifuge tubes and 
diluted with cold 1 mM NaHCO 3 and centrifuged at 
10000 X g in a HB rotor for 30 min. The purity of the 
plasma membrane was determined to be > 90% by elec- 
tron microscope morphometry. The yield was 20 mg plasma 
membrane protein from 10 ~° cells. 
2.3. Purification of plasma membranes from rat liver 
Rat liver plasma membranes were purified from the 
5000 X g pellet from the preparation of Golgi apparatus 
[21] which was the starting material. The fluffy layer 
which contains the Golgi apparatus was mixed, withdrawn 
and excluded from the plasma membrane preparations. 
Cold ! mM NaHCO 3 (5 ml) was added to each tube and 
the friable yellow-brown part of the pellet was resus- 
pended with a pen brush, leaving the reddish, tightly- 
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packed bottom part of the pellet undisturbed. The resus- 
pended material was homogenized in aliquots of 5 ml each 
in a 30 ml stainless steel (Duragrind) homogenizer 20 
times by hand. The homogenates were combined, diluted 
with cold 1 mM NaHCO 3 (1:1 dilution), and the pellet was 
used for the two-phase separation as described above for 
HeLa cell plasma membranes. 
The plasma membrane preparations from rat liver have 
been characterized xtensively based on both morphologi- 
cal and enzymatic riteria [20,22]. From morphometric 
analysis using electron microscopy, the preparations con- 
tained 90 + 4 percent plasma membrane. Contaminants 
included mitochondria (4%) and endoplasmic reticulum 
(3%). Based on analyses of marker enzymes, the contami- 
nation by endoplasmic reticulum was estimated to be 3%, 
that of mitochondria 15% and that of Golgi apparatus 1%. 
The yield of plasma membranes was estimated to average 
18% based on recovery of marker enzymes. 
Plasma membrane pellets were resuspended in 50 mM 
Tris-Mes buffer (pH 7.0) and stored at -70°C. Proteins 
were determined using the bichinchoninic acid (BCA) 
assay [23] with bovine serum albumin as standard. 
2.4. Spectrophotometric assay 
NADH oxidase activity was determined as the disap- 
pearance of NADH measured at 340 nm in a reaction 
mixture containing 25 mM Tris-Mes buffer (pH 7.2), 1 
mM KCN to inhibit any potential mitochondrial oxidase 
activity, and 150 /xM NADH at 37°C with constant stir- 
ring. Activity was measured using a Hitachi U3210 with 
continuous recording over 5 or 10 min intervals. A mil- 
limolar extinction coefficient of 6.22 was used to deter- 
mine NADH disappearance. 
3. Results 
The NADH oxidase activity of HeLa cell plasma mem- 
branes was characterized and shown to have steady-state 
characteristics similar to those of rat liver (Table 1). When 
assayed for sulfonylurea responsiveness, the NADH oxi- 
dase of the isolated plasma membrane vesicles of HeLa 
cells was inhibited by the antitumor active LY181984 but 
Table 1 
Characteristics of NADH oxidase activity comparing rat liver, rat hep- 
atoma and HeLa cell plasma membranes 
Characteristics Source of plasma membrane 
liver hepatoma HeLa 
pH optimum 7.0 7.0 7.0 
K m for NADH (~M)  ~ 25 = 25 = 25 
(0-30 ;zM NADH) 
Ion requirements none none none 
Specific activity 1.5-2.1 1.6-2.4 0.8-1.6 
(nmol/min per mg protein) 
Table 2 
NADH oxidase activity of plasma membranes from cultured cells and rat 
liver 
Cells or tissue NADH oxidase (nmol/min per mg protein) 
DMSO alone + LY181984 +LY181985 
HeLa cells 0.85+0.05 0.15+0.03 0.85+0.05 
Rat kidney cells 2.2 +0.09 2.2 +0.13 2.2 +0.11 
Rat liver 1.75 -t-0.3 1.8 -+0.2 1.75 -+0.2 
The sulfonylurea concentration was I ;xM. The final DMSO concentra- 
tion was 0.1%. 
not by the inactive LY181985 (Table 2, Fig. 1). With 
freshly isolated right side-out vesicles stored overnight at 
4°C, half maximal inhibition was at about 50 nM LY 181984 
and inhibition was about 90% at 1 /xM (Fig. 1). The 
inactive LY 181985 was without effect until 10 /~M where 
a slight (20%) inhibition was observed. 
With plasma membranes stored frozen and then thawed, 
the specific activity of the NADH oxidase was approx. 1.9 
that of freshly prepared vesicles but the overall degree of 
inhibition by the antitumor active LY181984 was only 
about 50% (Fig. 2). The antitumor inactive LY181985 was 
only slightly (about 10% at 10 /zM) inhibitory. 
When the response to increasing amounts of NADH 
was determined, the resultant kinetics were complex (Fig. 
3). At high NADH, the inhibition by LY181984 appeared to 
be uncompetitive. Both the K m and the Vma x were de- 
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Fig. 1. Inhibition of NADH oxidase activity of HeLa plasma membranes 
by increasing concentrations of LY 181984 (solid symbols) and LY 181985 
(open symbols). The antitumor active LY181984 inhibited NADH oxi- 
dase activity with sealed right-side-out vesicles. The chemically-related 
but antitumor inactive LY181985 required several og orders more drug 
to inhibit. For each experiment duplicate determinations were averaged. 
Results are based on averages of three experiments _. standard eviations 
among experiments. 
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Fig. 2. With plasma membranes that were stored frozen and then thawed, 
the NADH oxidase activity was inhibited by LY181984 (solid symbols) 
but not by LY 181985 (open symbols). The specific activity of the plasma 
membrane NADH oxidase was higher after freezing and thawing but the 
extent of inhibition by the antitumor active LY181984 was less that with 
freshly prepared, predominantly right side-out, vesicles (Fig. 1). The 
antitumor inactive LY181985 was only weakly inhibitory. For each 
experiment duplicate determinations were averaged. Results are based on 
averages of three experiments + standard eviations among experiments. 
creased in the presence of LY181984. However, at low 
NADH, the analyses approximated noncompetitive kinet- 
ics. The latter might indicate the presence of a high K m 
form of the oxidase differentially affected by the sulfonyl- 
ureas (Fig. 3B). With the frozen and thawed preparations 
averaged from 8 determinations, the apparent Vma x was 
0.5 + 0.2 nmol NADH oxidized per min per mg protein in 
the presence of LY181984 whereas in the absence of 
LY181984 the apparent Vma x was 1.2 _ 0.3 nmol NADH 
oxidized/min per mg protein. 
With freshly isolated vesicles, presumably sealed and 
predominantly fight side-out, kinetic analyses yielded pri- 
marily the low K m fo rm (K  m for NADH = 25-30/xM) of 
the activity at high NADH concentrations (Fig. 4). How- 
ever, at low NADH, an activity with an apparent K m for 
NADH of about 60 /xM also was observed which was no 
longer apparent at 1 /zM LY181984. The apparent Vma x in 
the absence of LY181984 was 1.3 nmol/min per mg 
protein, whereas in its presence at 1 /xM, the apparent 
Vma ~ was 0.15 nmol/min per mg protein. Results with 0.1 
/zM LY181984 were intermediate. 
Growth of attached HeLa cells in culture was reduced 
by the antitumor sulfonylurea LY181984 with an ECs0 of 
about 50 /xM (Fig. 5). It has generally been observed that 
transformed cells in culture were less responsive to the 
antitumor sulfonylureas than was the in vivo growth of 
solid tumors [10]. The antitumor inactive analog LY 181985 
was without effect on cell growth even at 100 /~M. With 
plasma membranes of HeLa cells, LY181984 but not 
LY 181985 inhibited as well in detergent-solubilized prepa- 
rations (Fig. 6). Specific activity was not increased by 
detergent compared to frozen and thawed vesicles and the 
maximum inhibition by LY181984 was about 50% with 
the detergent-solubilized activity (Fig. 6). 
Neither LY181984 nor LY181985 affected the NADH 
oxidase activity of plasma membranes of rat liver (Fig. 
7A). With liver plasma membranes, activity was unaf- 
fected by LY181984 even at concentrations a  high as 100 
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Fig. 3. The response of NADH oxidation by isolated vesicles of plasma membrane from HeLa cells frozen and thawed prior to assay. (A) As a function of 
NADH concentration and in the presence (open symbols) or absence (solid symbols) of 1 p,M LY181984. (B) A double reciprocal analysis yielded an 
apparent K m of 17/zM in the absence of LY 181984 at low NADH and of 27/zM at high NADH. In the presence of LY 181984, the apparent K m was 17 
k~M for both low and high NADH. For each experiment duplicate determinations were averaged. Results are based on averages of three experiments + 
standard eviations among experiments. 
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Fig. 4. Double reciprocal analysis of the response of NADH oxidation by 
sealed vesicles of plasma membrane from HeLa cells freshly isolated and 
maintained at 4°C prior to analysis comparing no LY181984, 0.1 /zM 
LY181984 and 1 /zM LY181984. In the absence of LY181984 (solid 
symbols), these vesicles yielded an apparent K m of 25-30 /xM at low 
NADH and of about 60 /xM at high NADH. With 1 IzM LY181984, the 
apparent K m of the remaining activity was about 30 ~M but the apparent 
lima X (0.15 nmol/min per mg protein) was greatly reduced from that in 
the absence of LY 181984 (1.3 nmol/min per mg protein). Results at 0.1 
/xM LY181984 were intermediate. For each experiment duplicate deter- 
minations were averaged. Results are based on averages of three experi- 
ments + standard eviations among experiments. 
/xM or with membranes olubilized with detergent (Fig. 
7B). As with HeLa, the specific activity of the detergent- 
solubilized membranes (Fig. 7B) was not significantly 
increased over that of frozen and thawed membranes (Fig. 
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Fig. 5. Growth of HeLa cells inhibited by the antitumor active sulfony- 
lurea LY181984 (open symbols). Several og orders more of the chemi- 
cally-related but antitumor inactive LY181985 (open symbols) were 
required to inhibit growth. Results are from two experiments+mean 
average determinations. 
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Fig. 6. Inhibition of NADH oxidase of detergent (0.1% Triton X-100)- 
solubilized HeLa plasma membranes by the antitumor active LY181984 
(solid symbols and lines) but not by the chemically-related but antitumor 
inactive LY181985 (open symbols and dashed lines). For each experi- 
ment duplicate determinations were averaged. Results are averages from 
three experiments ___ standard eviations among experiments. 
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Fig. 7. Response of NADH oxidase activity of rat liver plasma mem- 
branes to increasing concentrations of LY181984 (active, solid symbols 
and lines), LY181985 (inactive; open circles and dotted lines) or DMSO 
alone (open triangles and dotted lines) in the absence (A) or presence (B) 
of 0.1% Triton X-100. For each experiment, duplicate determinations 
were averaged. Results are averages from three experiments-t-standard 
deviations among experiments. 
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7A). As with liver plasma membranes, the NADH oxidase 
activity of normal rat kidney cells was unaffected by either 
1 /zM LY181984 or 1 tzM LY181985 (Table 2). 
4. Discussion 
Plasma membranes from HeLa cells bind 
[ 3 H]LY 181984, an active experimental sulfonylurea [ 10], 
with high affinity [1 ]. The binding protein has been identi- 
fied tentatively as a 34 kDa component of the plasma 
membrane containing N-ethylmaleimide-reactive thiols 
protected against reaction with N-ethylmaleimide in the 
presence of the active sulfonylurea LY181984 [2]. By 
analogy with a 36 kDa sulfonylurea-inhibited NADH oxi- 
dase activity from plants [3,4], a comparable sulfonylurea- 
inhibited NADH oxidase of plasma membranes from sul- 
fonylurea-responsive HeLa cells was sought. 
In this report, we demonstrate an NADH oxidase activ- 
ity of HeLa plasma membrane that is inhibited by the 
active experimental ntitumor sulfonylurea, LY 181984, but 
not by an inactive analog, LY181985. The NADH oxidase 
activity of liver plasma membranes which do not exhibit 
high affinity binding of LY181984 [1] was not inhibited by 
either LY181984 or LY181985. The findings implicate a 
34 kDa protein with NADH oxidase activity, having a 
plant counterpart [3,4], as the antitumor sulfonylurea-bind- 
ing protein. Inhibition by LY181984 of NADH oxidase 
activity of HeLa plasma membranes occurred at very low 
doses of drug with half maximal inhibition at about 50 nM. 
The concentration corresponded closely to the K d of 
[3H]LY181984 binding of 25 nM [1]. 
With predominantly intact, right side-out vesicles, the 
drug inhibited the NADH oxidase about 90%. However, 
with detergent-disrupted membranes, NADH oxidase activ- 
ity was inhibited only by about 50%. This degree of 
inhibition was exhibited at an optimum LY181984 concen- 
tration of about 1 p~M. When assays were conducted on 
populations of membrane vesicles that had been frozen and 
thawed to yield a mixture of inside-out and right side-out 
vesicles [24], the inhibition also was about 50%. The 
failure of LY181985 to inhibit more than 50% with these 
preparations suggests the presence in the membrane of two 
forms of the NADH oxidase, one inhibited by sulfony- 
iurea, the other not. 
With liver, many of the plasma membranes were iso- 
lated as sheets stabilized by junctional complexes o that 
both surfaces were exposed to drug and to the normally 
impermeant NADH substrate. Yet, the NADH oxidase 
activity of the plasma membrane preparations from rat 
liver were unresponsive to either of the sulfonylureas 
tested. 
Results similar to those with plasma membrane vesicles 
from HeLa cells were obtained with plasma membrane 
vesicles from a plant source, soybean stems. Here, chlor- 
sulfuron, a herbicidal sulfonylurea, inhibited both the 
NADH oxidase and the growth stimulated by the synthetic 
plant growth hormone, 2,4-D, but was without effect on 
the constitutive NADH oxidase activity or on growth 
observed in the absence of hormone [4]. Again, the results 
were suggestive of two forms of the NADH oxidase. One 
form was stimulated by the growth hormone and inhibited 
by the sulfonylurea. The other form was neither stimulated 
by the hormone nor was it inhibited by the sulfonylurea. 
The basis for the inhibition when analyzed kinetically 
was found to be complex. With plasma membrane vesicles 
from HeLa cells, the sulfonylurea lowered both the K m 
and Vma x to account for the inhibition seen at saturating 
NADH levels. Moreover, it appeared from the kinetic 
analyses that the high K m component of the NADH 
oxidase activity was reduced or eliminated by the addition 
of 1 /zM LY181984 (Figs. 3 and 4). This was especially 
evident with frozen and thawed vesicles which contained 
nearly equal amounts of an activity inhibited by LY181984 
and of an activity resistant to inhibition by LY 181984 (Fig. 
3). With isolated vesicles tored at 4°C but not frozen prior 
to assay, the high K m component was less abundant and 
the degree of inhibition resulting from LY 181984 addition 
was more nearly complete. Although not conclusive, the 
kinetic analyses not only support he overall indications of 
two NADH oxidase activities associated with the HeLa 
cell plasma membrane but further suggest hat it is the 
high K m, high Vma x component of the activity that is most 
susceptible to inhibition by LY181984. 
The plasma membrane vesicles disrupted either by de- 
tergent reatment or by freezing and thawing exhibited 
both sulfonylurea-inhibited and sulfonylurea-unresponsive 
NADH oxidase activities in nearly equal amounts on an 
activity basis. One possibility to explain the two forms 
would be an association of NADH oxidase activity with 
both the inner and the outer leaflets of the plasma mem- 
brane. The low Kin, low Vma x and sulfonylurea-resistant 
form of the activity would represent the former. The high 
Km, sulfonylurea-inhibited form of the activity would rep- 
resent he latter. 
The function of the plasma membrane NADH oxidase 
and especially of the growth factor and/or hormone- 
stimulated component [7] remains unknown. However, 
since the NADH oxidase of plasma membranes from 
transformed cells and tissues fails to respond to growth 
factors and hormones [8,9] but does respond to an antitu- 
mor sulfonylurea (this report), the oxidase, or some pro- 
teins associated with the response of the NADH oxidase to 
hormones and growth factors, does appear altered in re- 
sponse to transformation. As such the site altered in trans- 
formation might be both selective and effective as a poten- 
tial target for cell surface-directed antitumor drugs. 
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